These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15103748)

  • 21. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
    Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
    Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
    Sanhes L; Tang R; Delmer A; DeCaprio JA; Ajchenbaum-Cymbalista F
    Leukemia; 2003 Jun; 17(6):1104-11. PubMed ID: 12764376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
    Wolff D; Steiner B; Stilgenbauer S; Kahl C; Leithäuser M; Junghanss C; Wilhelm S; Kleine HD; Zimmermann R; Hartung G; Casper J; Freund M
    Eur J Haematol; 2004 Feb; 72(2):145-8. PubMed ID: 14962253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro.
    Furlan A; Villanova F; Pietrogrande F; Celadin M; Sanzari M; Vianello F
    Leuk Lymphoma; 2010 Jan; 51(1):107-13. PubMed ID: 20001234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.
    Smolewski P; Szmigielska-Kaplon A; Cebula B; Jamroziak K; Rogalinska M; Kilianska Z; Robak T
    Leuk Lymphoma; 2005 Jan; 46(1):87-100. PubMed ID: 15621786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
    Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
    Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
    Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.
    Kennedy B; Rawstron A; Carter C; Ryan M; Speed K; Lucas G; Hillmen P
    Blood; 2002 Mar; 99(6):2245-7. PubMed ID: 11877305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.
    Montillo M; Tedeschi A; Rossi V; Cairoli R; Pungolino E; Intropido L; Cafro AM; D'Avanzo G; Farioli R; Brando B; Scarpati B; Veronese S; Morra E
    Leukemia; 2004 Jan; 18(1):57-62. PubMed ID: 14586480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
    de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
    Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
    Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo 'purging' of residual disease in CLL with Campath-1H.
    Dyer MJ; Kelsey SM; Mackay HJ; Emmett E; Thornton P; Hale G; Waldmann H; Newland AC; Catovsky D
    Br J Haematol; 1997 Jun; 97(3):669-72. PubMed ID: 9207420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
    Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.
    Nabhan C; Rosen ST
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):75-80. PubMed ID: 11842392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.